BPOM Uncovers Novel Chemical Adulteration in Traditional Herbal Products with Pyrimidenafil Discovery

The Indonesian Food and Drug Authority (Badan Pengawas Obat dan Makanan, or BPOM) has made a groundbreaking and alarming discovery in the nation’s pharmaceutical and traditional medicine oversight, identifying a novel chemical substance previously undetected in local herbal products. In a routine yet increasingly complex market surveillance operation, regulatory scientists detected the presence of pyrimidenafil—a synthetic chemical drug substance—hidden within traditional medicine products, widely known locally as jamu or obat bahan alam (OBA). This revelation marks a critical turning point in how regulatory bodies monitor consumer safety, highlighting an escalating cat-and-mouse game between clandestine manufacturers and health authorities determined to protect public health.

The inclusion of synthetic drugs in herbal preparations is not a novel regulatory infraction; however, the specific identification of pyrimidenafil represents an unprecedented evolution in illegal manufacturing tactics. Historically, producers seeking to artificially boost the efficacy of stamina-enhancing traditional remedies relied on well-known phosphodiesterase-5 (PDE5) inhibitors such as sildenafil and tadalafil. The sudden appearance of pyrimidenafil, a pharmacologically active synthetic compound with similar mechanisms of action but a distinct chemical structure, signals a calculated attempt by illicit manufacturers to bypass standard laboratory screening protocols and evade regulatory detection.

Unprecedented Detection and Regulatory Alarm

The disclosure was officially announced by BPOM Head Taruna Ikrar, who underscored the severity of the situation. According to official statements released by the agency, the detection of pyrimidenafil is being treated as a high-priority concern due to its status as a newly identified chemical adulterant in the Indonesian traditional medicine landscape.

"The finding of pyrimidenafil is a matter of serious concern for BPOM because it is a type of chemical drug substance (BKO) that we have identified for the first time in the supervision of natural medicinal products in Indonesia," Taruna stated. He further elaborated that the introduction of an alternative compound—one structurally distinct from traditionally monitored adulterants—points directly to deliberate malicious intent. "The use of a compound different from the BKO commonly found so far is suspected to be one of the modus operandi of irresponsible actors to outwit product supervision and testing."

Laboratory analyses confirmed that pyrimidenafil was embedded within three distinct traditional medicine products marketed specifically for male vitality and stamina: EXIE, YUBOKKI, and DURAMAX. All three implicated formulations were traced back to a single manufacturing facility operated by PT Bintang Kupu-Kupu, located in Tangerang, Banten. The revelation has prompted an immediate, aggressive response from regulatory authorities, who view the incident not merely as an isolated compliance failure, but as a sophisticated shift in illegal product adulteration patterns.

Understanding Pyrimidenafil and Its Pharmacological Risks

Pyrimidenafil functions biochemically as an inhibitor of the phosphodiesterase-5 (PDE5) enzyme, mirroring the foundational mechanism of action found in prescription medications designed to treat erectile dysfunction, most notably sildenafil (commonly marketed as Viagra). By inhibiting PDE5, the compound relaxes smooth muscles and enhances blood flow to specific regions of the body, temporarily augmenting sexual function.

However, the surreptitious inclusion of such active pharmaceutical ingredients (APIs) in over-the-counter herbal remedies poses severe, unquantified health risks to consumers. Traditional medicines are marketed and perceived by the general public as natural, safe, and free from the side effects associated with synthetic drugs. When unsuspecting consumers ingest products containing clandestine synthetic chemicals like pyrimidenafil, they are exposed to significant pharmacological hazards without medical supervision.

Unmonitored consumption of PDE5 inhibitors can precipitate dangerous drops in blood pressure, particularly in individuals with pre-existing cardiovascular conditions or those concurrently taking nitrate-based medications for heart disease. Furthermore, because herbal products do not list precise dosage guidelines for these hidden drugs, consumers face a high probability of accidental overdose, triggering adverse reactions ranging from severe headaches and visual disturbances to life-threatening cardiovascular events.

The Broader Scope of Herbal Adulteration in Indonesia

While the discovery of pyrimidenafil represents a novel frontier in adulteration techniques, it is part of a much larger, systemic challenge facing Indonesian regulators. Alongside the specific crackdown on the Tangerang-produced items, BPOM’s nationwide surveillance data covering the period up to July 2026 revealed a staggering total of 35 separate traditional medicine items operating completely without marketing authorization (Tanpa Izin Edar, or TIE) that were simultaneously laced with various other prohibited chemical drug substances.

Laboratory profiling of these unauthorized products uncovered a cocktail of dangerous synthetic additives, including sildenafil, sibutramin (an anorectic agent previously withdrawn from the market due to cardiovascular risks), deksametason (a potent corticosteroid capable of causing severe hormonal imbalances and immunosuppression), and paracetamol, alongside a rotating roster of other previously identified chemical compounds.

This pervasive trend demonstrates that the illicit practice of spiking traditional remedies with modern pharmaceuticals remains an active, lucrative, and resilient black-market enterprise. Manufacturers of these illegal products frequently exploit cultural preferences for traditional, plant-based remedies, capitalizing on consumer desires for rapid, guaranteed physiological results—such as instant stamina boosts or immediate relief from joint pain and fatigue—while disregarding federal safety mandates.

Swift Regulatory Actions and Enforcement Measures

In response to the confirmed laboratory results, BPOM has moved swiftly to neutralize the immediate threat posed by the adulterated products. The agency officially revoked the marketing authorizations for the three specific formulations—EXIE, YUBOKKI, and DURAMAX—effectively banning their sale, distribution, and advertising nationwide. Concurrently, rigorous legal and administrative actions are being initiated against PT Bintang Kupu-Kupu and any associated distribution networks involved in the supply chain.

For the broader category of 35 unauthorized TIE products discovered during the mid-2026 surveillance sweep, BPOM has mandated immediate product recalls and coordinated with law enforcement agencies to pursue structural penalties under Indonesian health and consumer protection laws. These measures reflect a zero-tolerance policy toward illegal manufacturing practices that directly jeopardize public safety.

Despite these aggressive enforcement actions, regulatory bodies acknowledge that policing the vast and decentralized herbal medicine market presents formidable logistical challenges. Illicit producers frequently shift production sites, alter brand names, or utilize digital marketplaces and social media platforms to market their adulterated goods directly to consumers, bypassing traditional brick-and-mortar retail audits.

Technological Adaptation and Surveillance Enhancements

The successful detection of pyrimidenafil highlights both the persistent threats in the pharmaceutical supply chain and the growing sophistication of Indonesia’s national regulatory apparatus. In the wake of this discovery, BPOM has emphasized its ongoing commitment to outpacing illegal manufacturers through continuous investment in advanced analytical methodologies and laboratory infrastructure.

To counter the use of novel chemical analogues and modified drug structures designed specifically to evade standard testing procedures, BPOM has systematically expanded its testing scopes. The agency is currently upgrading its analytical capabilities to include high-resolution mass spectrometry and advanced chromatographic techniques capable of identifying structural variants, chemical derivatives, and novel synthetic compounds that have never before been cataloged in standard screening libraries.

Furthermore, regulatory oversight has been broadened across digital commerce ecosystems. Recognizing that a significant volume of unauthorized and adulterated traditional medicines are now traded via e-commerce platforms and social media advertisements, BPOM has intensified cyber-patrolling operations in collaboration with digital platform operators to intercept illegal sales before they reach consumers.

Public Awareness and Consumer Protection Guidelines

As regulatory agencies ramp up enforcement and technological detection capabilities, BPOM has issued renewed public warnings urging consumers to exercise extreme vigilance when purchasing and consuming traditional health products. The agency stresses that public cooperation remains a critical line of defense against the proliferation of illegal pharmaceuticals disguised as natural remedies.

Consumers are strongly advised to adopt a highly critical mindset toward health products that feature exaggerated, unrealistic marketing claims. Advertisements promising "instant stamina enhancement," "miraculous muscle pain relief in minutes," or guaranteed rapid therapeutic transformations are primary indicators of potential chemical adulteration. Legitimate traditional medicines require time to manifest physiological effects and cannot legally contain potent, fast-acting synthetic drugs.

To minimize health risks, the public is encouraged to adhere to several foundational safety practices:

• Verify Marketing Authorization: Always check product packaging for official BPOM registration numbers and verify their authenticity through the official BPOM mobile application or website before purchase.
• Source Reliability: Purchase traditional medicines and health supplements exclusively through authorized, trusted retail outlets, registered pharmacies, and official brand stores rather than unverified online sellers or direct-message social media accounts.
• Scrutinize Labeling: Carefully inspect product labeling, manufacturing information, and expiration dates. Vague labeling, missing corporate addresses, or foreign packaging lacking Indonesian translation are immediate red flags.
• Report Suspicious Products: Consumers who encounter suspicious health products or experience unexpected adverse side effects after consuming traditional remedies are urged to report their findings directly to BPOM through official reporting channels.

Broader Implications for the Traditional Medicine Industry

The unmasking of pyrimidenafil as a novel adulterant carries profound implications for the legitimate Indonesian traditional medicine (jamu) industry. The sector, which represents a vital component of the nation’s cultural heritage and economic landscape, relies heavily on consumer trust, quality assurance, and international export potential.

Incidents of widespread chemical adulteration threaten to cast a shadow over compliant manufacturers who adhere strictly to Good Manufacturing Practices (CPOTB – Cara Pembuatan Obat Tradisional yang Baik). When rogue producers introduce synthetic drugs into herbal matrices, they not only endanger consumer lives but also undermine the economic viability and global reputation of legitimate local herbal enterprises.

Industry stakeholders and trade associations have increasingly called for stricter self-regulation, peer oversight, and harsher penalties for rogue operators who tarnish the industry’s image. Experts emphasize that restoring absolute consumer confidence will require a multi-faceted approach combining unyielding regulatory enforcement, continuous technological innovation in drug testing, and sustained public education campaigns.

Ultimately, the pyrimidenafil case serves as a stark reminder of the evolving complexities inherent in modern health product regulation. As illicit manufacturers continue to innovate in their attempts to bypass safety controls, regulatory bodies like BPOM must maintain an equally adaptive posture—balancing rigorous scientific surveillance with proactive public engagement to safeguard public health across the nation.